Department of Family Medicine, School for Public Health and Primary Care (CAPHRI), Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands.
Department of Health, Ethics and Society, School for Public Health and Primary Care (CAPHRI), Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands.
Vaccine. 2018 May 17;36(21):2991-2997. doi: 10.1016/j.vaccine.2018.04.027.
The effectiveness of influenza vaccination in the elderly has long been a topic of debate, fueled by the absence of direct evidence from randomized trials on its effect on mortality and the methodological limitations of observational studies pointing this direction. It is argued that new placebo-controlled trials should be undertaken to resolve this uncertainty. However, such trials may be ethically questionable. To bring this discussion forward, we provide a comprehensive overview of the ethical challenges of an influenza vaccine efficacy trial designed to evaluate mortality in the elderly. An important condition in the justification of a trial is the existence of genuine uncertainty in regard to the answer to a research question. Therefore an extensive analysis of the existing levels of knowledge is needed to support the conclusion that an effect of vaccination on mortality is uncertain. Even if a so called "clinical equipoise" status applies, denying a control group vaccination would be problematic because vaccination is considered "competent care" and withholding vaccination could substantially increase patients' risk for influenza and its complications. Given the high burden of disease and already proven benefits of vaccination, such a trial is unlikely to meet the Declaration of Helsinki stating that the importance of a trial must outweigh the risk patients are exposed to. While a placebo-controlled trial in vaccine refusers may be considered, such a trial is unlikely to meet substantial methodological barriers regarding trial size and generalizability. We conclude that a new trial is unlikely to provide for a direct answer, let alone change current policy. At the same time, given the lack of consensus on the ethical acceptability of a placebo-controlled trial on the effect of influenza vaccination on mortality in the elderly, we invite researchers considering such trials to address the ethical challenges discussed in this manuscript.
流感疫苗在老年人中的有效性一直是一个备受争议的话题,这主要是因为缺乏随机试验直接证明其对死亡率的影响,以及指向这一方向的观察性研究方法学上的局限性。有人认为,应该开展新的安慰剂对照试验来解决这一不确定性。然而,此类试验可能在伦理上存在问题。为了推进这一讨论,我们全面概述了旨在评估老年人死亡率的流感疫苗效力试验所面临的伦理挑战。试验合理性的一个重要条件是,对于研究问题的答案存在真正的不确定性。因此,需要对现有知识水平进行广泛分析,以支持这样一种结论,即疫苗对死亡率的影响存在不确定性。即使存在所谓的“临床均衡状态”,拒绝为对照组接种疫苗也会有问题,因为接种疫苗被认为是“适当的护理”,而不接种疫苗可能会大大增加患者患流感及其并发症的风险。鉴于疾病负担高,并且已经证明疫苗接种有好处,这样的试验不太可能符合《赫尔辛基宣言》的要求,即试验的重要性必须超过患者面临的风险。虽然可以考虑对疫苗拒绝者进行安慰剂对照试验,但这种试验不太可能在试验规模和普遍性方面克服实质性的方法学障碍。我们的结论是,一项新的试验不太可能提供直接的答案,更不用说改变当前的政策了。同时,鉴于在缺乏共识的情况下,关于安慰剂对照试验对流感疫苗对老年人死亡率的影响的伦理可接受性,我们邀请考虑此类试验的研究人员来解决本文讨论的伦理挑战。